Risk factors for placenta accreta spectrum: findings from the Japan environment and Children’s study

Kyozuka, Hyo; Yamaguchi, Akiko; Suzuki, Daisuke; Fujimori, Keiya; Hosoya, Mitsuaki; Yasumura, Seiji; Yokoyama, Tadahiko; Satô, Akiko; Hashimoto, Koichi

doi:10.1186/s12884-019-2608-9

Cited by 87 publications

(88 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Further investigation is necessary since GnRHa therapy is a widely used medication both in IVF protocols, in treatment of endometriosis, and more recently in patients with adenomyosis. Pregnancies conceived after IVF do have an increased risk for subsequent placenta accreta [ 15 , 16 ]. These studies did not compare GnRH agonist vs GnRH antagonist protocols, but that could be a potential area of study in the future [ 15 , 16 , 21 , 22 ].…”

Section: Discussionmentioning

confidence: 99%

“…Pregnancies conceived after IVF do have an increased risk for subsequent placenta accreta [ 15 , 16 ]. These studies did not compare GnRH agonist vs GnRH antagonist protocols, but that could be a potential area of study in the future [ 15 , 16 , 21 , 22 ]. Although larger studies have shown that endometriosis is associated with increased risk for placenta accreta, smaller studies did not find an association as it was a rare outcome [ 23 – 25 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A rare case of extensive placenta accreta in twin pregnancy after GnRH agonist treatment of adenomyosis

Agrawala

Patil

Campbell

et al. 2021

Fertil Res and Pract

View full text Add to dashboard Cite

Background Adenomyosis remains an enigma for the reproductive endocrinologist. It is thought to contribute to sub-fertility, and its only curative treatment is hysterectomy. However, studies have documented increased live birth rates in women with adenomyosis who were treated with gonadotropin releasing hormone agonist (GnRHa). Case Here we present a case of a 52-year-old woman with adenomyosis who had three failed frozen embryo transfers (FETs) prior to initiating a 6-month trial of GnRHa. GnRHa therapy resulted in a decrease in uterine size from 11.5 × 7.9 × 7.0 cm to 7.8 × 6.2 × 5.9 cm and a decrease in the junctional zone (JZ) thickness from 19 to 9 mm. Subsequently, she underwent her fourth FET, which resulted in live birth of twins. The delivery was complicated by expansive accretas of both placentas requiring cesarean hysterectomy. The final pathology of the placentas demonstrated an extensive lack of decidualized endometrium that was even absent outside the basal plate. Conclusions GnRHa therapy in patients with adenomyosis may improve implantation rates after FET. Previous molecular studies indicate that genetic variance in the expression of the gonadotropin releasing hormone receptor (GnRHR) could explain the expansive lack of decidualized endometrium after GnRHa therapy. Further investigations are needed to determine if GnRHa therapy contributes to the pathologic process of placenta accreta.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A rare case of extensive placenta accreta in twin pregnancy after GnRH agonist treatment of adenomyosis

Agrawala

Patil

Campbell

et al. 2021

Fertil Res and Pract

View full text Add to dashboard Cite

show abstract

“…Kyozuka et al . 9) recently reported that undergoing CS two or more times, smoking during pregnancy, becoming pregnant through assisted reproductive technology, and uterine anomalies are all independent risk factors for unexpected PAS in the absence of placenta previa. Therefore, it is crucial to maintain a high index of suspicion for PAS during the antenatal period in patients with these risk factors, even without placenta previa.…”

Section: Discussionmentioning

confidence: 99%

Late-diagnosed cesarean scar pregnancy resulting in unexpected placenta accreta spectrum necessitating hysterectomy

Suzuki

Kyozuka

Fukuda

et al. 2020

FJMS

Self Cite

View full text Add to dashboard Cite

Cesarean scar pregnancy (CSP) is a rare complication involving the implantation of the gestational sac in a cesarean delivery scar. The authors report a case of unexpected placenta accreta spectrum (PAS) caused by late diagnosed CSP, necessitating emergent hysterectomy. A 28-year-old Japanese woman with two previous cesarean deliveries presented to our hospital at 11 weeks of gestation with abnormal transvaginal ultrasound findings obtained at another hospital;however, transabdominal ultrasound revealed that the fetus was already present in the uterine cavity at this time. At 28 weeks, there was no evidence of placenta previa. The woman developed preeclampsia at 29 weeks, and a cesarean section was conducted. Intraoperative findings confirmed PAS, and hysterectomy was conducted immediately.

show abstract

“…The most important risk factors of PAS are previous C/S and intrauterine operation [10][11][12]. Other risk factors included placenta previa, multiparity, maternal age, any previous uterine surgery, surgical abortion, radiation, endometrial ablation, in vitro fertilization (IVF), chemotherapy, and adenomyosis [7,[10][11][12].…”

Section: Introductionmentioning

confidence: 99%

“…The rate of C/S in the United States is 32-33% and placentas accreta is equal to 1/540-1/2500 of total deliveries [1]. It has increased since the early 1900s and according to one meta-analysis , overall prevalence of PAS is 0.17% (range from 0.01 -1.1% ) [12,13]. The rate of PAS in women with placenta previa without previous C/S is 3% and with 1, 2, 3 times C/S reaches 11%, 40%, and 60%, respectively [1].…”

Section: Introductionmentioning

confidence: 99%

Predictive value of vascular endothelial growth factor and placenta growth factor for morbidly adherent placenta among women with previous history of cesarean section

Asadi¹,

Akbarzadeh‐Jahromi²,

Faraji³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background The present study aims to determine the predictive value of vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) for placenta accreta and for the comparison of the serum level of VEGF and PLGF in normal pregnant women and women with placenta accreta spectrum (PAS).Methods This prospective case-control study was conducted during the 2 years in two hospital in Shiraz, Iran from 2017 to 2019. The inclusion of the study was 90 singleton pregnant women: 45 of them in gestational ages of 28-34 weeks with pathological confirmation of placenta accreta spectrum and 45 healthy pregnant women. In the PAS group, according to pathology reports on the placenta, we divided all cases to placenta accreta, percreta, and increta. Maternal serum level of VEGF and PLGF were measured before the termination of pregnancy and diagnostic accuracy of each factor was evaluated.Results In PAS group, 75 percent of patients had placenta previa and unlike the control group, there was a significant difference in the gravidity, number of cesarean section, maternal age, and serum level of PLGF (p< /001); while in VEGF, the difference was not statistically significant. ConclusionsThe results of the present study revealed that the maternal serum level of PLGF could be considered as an accurate predictive test in patients with PAS. BackgroundWith the rising rate of cesarean section (C/S) worldwide, placenta accreta is considered as a new pathological matter [1]. According to the depth of invasion of placenta to myometrium, the placenta accreta spectrum (PAS), formerly known as morbidly adherent placenta, is divided into three groups: placenta accreta with superficial myometrial invasion, placenta increta with deep myometrial invasion, and placenta percreta with deep invasion of placenta to serosa of uterus and sometime to adjacent organs [1,2].In normal placentation, extravillous trophoblasts containing interstitial and endovascular cells invade decidua and superficial myometrium and cause remodeling of the basilar and spiral artery [3, 4].Thus, excessive trophoblastic invasion, abnormal decidualization, abnormal angiogenesis, and 4 decrease of apoptosis of trophoblasts can result in abnormal adherence of placenta [5, 6].In uterine scars such as site of C/S, total or partial absence of decidua, thinning, irregularity or absence of Nitabuch's layer, and subsequently, placenta accreta can happen [4,[7][8][9].Also, deficient trophoblastic invasion can be harmful and is related to abortion, preeclampsia, intrauterine growth restriction (IUGR), and preterm delivery [3].The most important risk factors of PAS are previous C/S and intrauterine operation [10][11][12]. Other risk factors included placenta previa, multiparity, maternal age, any previous uterine surgery, surgical abortion, radiation, endometrial ablation, in vitro fertilization (IVF), chemotherapy, and adenomyosis [7,[10][11][12].The rate of C/S in the United States is 32-33% and placentas accreta is equal to 1/540-1/2500 of total deliveries[1]. It has increased...

show abstract

Risk factors for placenta accreta spectrum: findings from the Japan environment and Children’s study

Cited by 87 publications

References 28 publications

A rare case of extensive placenta accreta in twin pregnancy after GnRH agonist treatment of adenomyosis

A rare case of extensive placenta accreta in twin pregnancy after GnRH agonist treatment of adenomyosis

Late-diagnosed cesarean scar pregnancy resulting in unexpected placenta accreta spectrum necessitating hysterectomy

Predictive value of vascular endothelial growth factor and placenta growth factor for morbidly adherent placenta among women with previous history of cesarean section

Contact Info

Product

Resources

About